Tectonic Therapeutic, Inc. Common Stock (TECX) Stock
Key stats
- Market cap
- $429.30M
- Price / Earnings ratio
- -5.0x
- EPS (TTM)
- -$4.63
- Volume
- Loading
- 52-week high
- $39.53
- 52-week low
- $16.77
Source: third-party data provider, as of November 13, 2026
Compare with TECX
Recent news
No recent news
Technical indicators
- RSI 14
- 51.95
- MACD 12/26/9
- -0.67
- EMA 9 of MACD
- -1.16
- MACD histogram
- 0.49
- SMA 50
- $23.67
- Price below SMA 50
- EMA 50
- $23.56
- Price below EMA 50
- SMA 200
- $28.13
- Price below SMA 200
- EMA 200
- $25.61
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About Tectonic Therapeutic, Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Alise S. Reicin M.D., Ph.D. | President, CEO, Secretary & Director | 1961 |
| Mr. Daniel Lochner M.B.A. | Chief Financial Officer | 1982 |
| Dr. Marcella Kuhlman Ruddy M.D., M.S. | Chief Medical Officer | 1963 |
| Mr. Washington Alves M.S. | Senior Vice President of Technical Operations | — |
| Dr. Peter McNamara Ph.D. | Chief Scientific Officer | 1972 |
| Ms. Geraldine Peters-Wiles | Senior Vice President of Human Resources | — |
| Mr. Anthony Muslin M.D. | Chief Development Officer | — |
| Dr. Marc Schwabish Ph.D. | Chief Business Officer | 1980 |
| John Diener | Senior Vice President of Antibody Engineering & Protein Sciences | — |
| Ms. Mary West M.S. | Senior Vice President of Clinical Development Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.95
- MACD 12/26/9
- -0.67
- EMA 9 of MACD
- -1.16
- MACD histogram
- 0.49
- SMA 50
- $23.67
- Price below SMA 50
- EMA 50
- $23.56
- Price below EMA 50
- SMA 200
- $28.13
- Price below SMA 200
- EMA 200
- $25.61
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $26.00
- Average
- $26.00
- High
- $26.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +11.4 | +34.4 | -9.1 | +7.3 | +19.0 | -14.4 | +7.2 | -25.4 | -12.7 | +15.7 |
